Cabozantinib in Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.Nature medicine · 2023
   Trial
2. Utilization of immunotherapy as a neoadjuvant treatment in liver transplant recipients with hepatobiliary carcinoma.Frontiers in oncology · 2026
   Article
3. Epigenetic drugs against human DNA viruses and retroviruses.Antiviral research · 2025
   Review
4. Spectrum of therapeutic options in hepatocellular carcinoma.Journal of exercise rehabilitation · 2025
   Review
5. Albumin-Bilirubin Score at Post-Hepatectomy Hepatocellular Carcinoma Recurrence: Impact on Survival and Association with Post-Hepatectomy Liver Failure.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
   Article
6. Editorial comment on: "Hepatobiliary surgery and nutrition · 2022
   Article
7. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
   Review
8. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.Journal of clinical medicine · 2021
   Review
9. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future.Cancers · 2021
   Review
10. Implications of Immunotherapy in Hepatobiliary Tumors.Visceral medicine · 2019
    Review

Corrections and comments

• Comment on
  Cabozantinib in Hepatocellular Carcinoma.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as